Endothelial destabilization by angiopoietin-2 via integrin β1 activation

Male 0301 basic medicine VE-CADHERIN Mice, Transgenic RECEPTOR TYROSINE KINASE Real-Time Polymerase Chain Reaction ANGIOGENESIS Article Cell Line Angiopoietin-2 Mice 03 medical and health sciences TIE2 RECEPTOR SDG 3 - Good Health and Well-being Pregnancy SELECTIVE-INHIBITION Angiopoietin-1 Animals Humans ALPHA-V-BETA-3 CELL-JUNCTIONS VASCULAR LEAK TUMOR-GROWTH Integrin beta1 ta1182 Endothelial Cells Receptor, TIE-2 Biomedicine Female LUNG INJURY
DOI: 10.1038/ncomms6962 Publication Date: 2015-01-30T14:28:03Z
ABSTRACT
AbstractAngiopoietins regulate vascular homeostasis via the endothelial Tie receptor tyrosine kinases. Angiopoietin-1 (Ang1) supports endothelial stabilization via Tie2 activation. Angiopoietin-2 (Ang2) functions as a context-dependent Tie2 agonist/antagonist promoting pathological angiogenesis, vascular permeability and inflammation. Elucidating Ang2-dependent mechanisms of vascular destablization is critical for rational design of angiopoietin antagonists that have demonstrated therapeutic efficacy in cancer trials. Here, we report that Ang2, but not Ang1, activates β1-integrin, leading to endothelial destablization. Autocrine Ang2 signalling upon Tie2 silencing, or in Ang2 transgenic mice, promotes β1-integrin-positive elongated matrix adhesions and actin stress fibres, regulating vascular endothelial-cadherin-containing cell–cell junctions. The Tie2-silenced monolayer integrity is rescued by β1-integrin, phosphoinositide-3 kinase or Rho kinase inhibition, and by re-expression of a membrane-bound Tie2 ectodomain. Furthermore, Tie2 silencing increases, whereas Ang2 blocking inhibits transendothelial tumour cell migration in vitro. These results establish Ang2-mediated β1-integrin activation as a promoter of endothelial destablization, explaining the controversial vascular functions of Ang1 and Ang2.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (55)
CITATIONS (233)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....